Mesoblast is aiming to get 2012 approval for bone marrow treatment

05/12/2010 | Bloomberg Businessweek

Mesoblast, an Australian company that develops stem cell treatments, has agreed to acquire the remaining shares of Angioblast Systems that it doesn't yet own. The acquisition will give Mesoblast exclusive rights to various treatments, including a stem cell treatment that expands umbilical cord blood used in bone marrow transplants among leukemia patients. Mesoblast hopes to get the treatment approved by 2012.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT